Fosphenytoin vs Oxcarbazepine (Oxtellar XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Fosphenytoin
Marketed by Pfizer
NCT01960075 · Phase 3 · completed
This randomized, triple-blind phase 3 trial (ESETT) compared intravenous fosphenytoin, valproic acid and levetiracetam in 478 enrolments with benzodiazepine-refractory status epilepticus. The primary endpoint was clinical cessation of status epilepticus within 60 minutes. The trial stopped early for futility under a prespecified rule; in the intention-to-treat analysis of the first 400 patients, seizures stopped in 53 of 118 participants on fosphenytoin, 56 of 121 on valproic acid and 68 of 145 on levetiracetam, and no arm was shown to be superior.
No aligned efficacy figure on record for this race.
Oxcarbazepine (Oxtellar XR)
Marketed by Supernus Pharmaceuticals
NCT00772603 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and included 366 participants, with seizure frequency as a clinical primary endpoint. The 2,400-mg comparison significantly favored oxcarbazepine, while the 1,200-mg comparison did not, so the primary result was mixed rather than consistently positive.
Reported efficacy
Percent Change in Seizure Rate (one year): Percent Change in Seizure Rate (one year): Oxcarbazepine XR -26.3 percentage of change in seizure rate (range -100 to 344.7) (not_applicable)
Result source: NCT00908349
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Fosphenytoin | Oxcarbazepine (Oxtellar XR) |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00908453 | —Not reported |
| 50% responder rate | —Not posted · NCT00908453 | 50% vs 34%+16 vs placeboNCT007726031 other result
|
| Seizure freedom | —Not posted · NCT00908453 | —Not reported |
Seizure frequency, % change
- Fosphenytoin
- —Not posted · NCT00908453
- Oxcarbazepine (Oxtellar XR)
- —Not reported
50% responder rate
- Fosphenytoin
- —Not posted · NCT00908453
- Oxcarbazepine (Oxtellar XR)
- 50% vs 34%+16 vs placeboNCT00772603
1 other result
- 44% vs 34% NCT00772603
Seizure freedom
- Fosphenytoin
- —Not posted · NCT00908453
- Oxcarbazepine (Oxtellar XR)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Fosphenytoin: 3 of 4 rows · Oxcarbazepine (Oxtellar XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fosphenytoin | Oxcarbazepine (Oxtellar XR) |
|---|---|---|
| Dropout rate | 38.2%a NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result—400mg NCT01458522 · Phase 2 · registry result, not featured evidence | 42.3%2400 mg/dayb NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results32.8%1200 mg/day NCT00772603 · Phase 3 · Epilepsy · phase 3 16.4% NCT00908349 · Phase 3 · monotherapy |
| Discontinued due to AEs | —a NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result—400mg NCT01458522 · Phase 2 · registry result, not featured evidence | 30.1%2400 mg/dayb NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results14.8%1200 mg/day NCT00772603 · Phase 3 · Epilepsy · phase 3 4.7% NCT00908349 · Phase 3 · monotherapy |
| Serious AEs | 0%a NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result22.2%400mg NCT01458522 · Phase 2 · registry result, not featured evidence | 8.1%2400 mg/dayb NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results5.7%1200 mg/day NCT00772603 · Phase 3 · Epilepsy · phase 3 8.4% NCT00908349 · Phase 3 · monotherapy |
| Most frequent reported AEs | a dizziness 9.2% fatigue 9.2% burning at the iv site 6.6% NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result400mg respiratory failure 6.7% acute respiratory failure 4.4% bradycardia 4.4% NCT01458522 · Phase 2 · registry result, not featured evidence | 2400 mg/dayb dizziness 40.7% (placebo 14.9%) headache 15.4% (placebo 7.4%) vomiting 15.4% (placebo 9.1%) NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results1200 mg/day dizziness 19.7% (placebo 14.9%) somnolence 11.5% (placebo 9.1%) diplopia 9.8% (placebo 4.1%) NCT00772603 · Phase 3 · Epilepsy · phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fosphenytoin
Oxcarbazepine (Oxtellar XR)
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fosphenytoin's landscape · Oxcarbazepine (Oxtellar XR)'s landscape